Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CCNC | P24863 | 5/20 | 0.40 |
| ▸ | CDK8 | P49336 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579695 | 0.84 | CCNC (0.52) | CCNCCDK8HDAC8NPC1 | |
| SCHEMBL15742867 | 0.84 | CNR1 (0.39) | ALDH1A1MAPTKDM4ECCNCCDK8 | |
| SCHEMBL1319809 | 0.82 | CCNC (0.49) | CCNCCDK8ADORA3 | |
| SCHEMBL15741600 | 0.80 | CCNC (0.38) | ALDH1A1CCNCCDK8 | |
| SCHEMBL15742716 | 0.80 | SCN9A (0.43) | CCNCCDK8 | |
| SCHEMBL29850571 | 0.80 | CCNC (0.47) | ALDH1A1MAPTKDM4ECCNCCDK8 | |
| SCHEMBL578828 | 0.80 | CCNC (0.47) | ALDH1A1MAPTKDM4ECCNCCDK8 | |
| SCHEMBL4580627 | 0.80 | SMYD3 (0.42) | CCNCCDK8 | |
| SCHEMBL15742739 | 0.79 | HPGD (0.55) | ALDH1A1MAPTKDM4ECYP1A2NPC1 | |
| SCHEMBL15742746 | 0.79 | SMN1; SMN2 (0.52) | ALDH1A1GAAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | ALDH1A1 1752/4885MAPT 4243/4885GAA 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.